slv-154
mAbexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 14, 2025 (NCT06771219)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Breast Neoplasms · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Carcinoma, Transitional Cell · Phase 1
- Endometrial Neoplasms · Phase 1
- Head and Neck Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 1
- Sarcoma · Phase 1
- Small Cell Lung Carcinoma · Phase 1
- Thyroid Neoplasms · Phase 1
- Uterine Cervical Neoplasms · Phase 1
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06771219 | Phase 1 | May 14, 2025 | Solve Therapeutics |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Solve Therapeutics | For profit | 1 | 1 | 1 | 2025 |
1 organizations
Page 1 / 1